Sanofi saw risk of Maze's drug 'dislodging its own dominance,' US FTC complaint says
MLex Summary: Sanofi recognized that Maze Therapeutics' drug for Pompe disease risked "dislodging its own dominance," the US Federal Trade Commission said in a complaint to block an exclusive licensing deal...To view the full article, register now.
Already a subscriber? Click here to view full article